Table 1. Patient characteristics.

	Panel I (n = 14)	Panel II (n = 51)	P*
Median Age (range), years	65.2 (45.8–78.3)	63.8 (38.8–80.4)	0.380
Gender, No. (%)
Female	6 (42.9)	16 (31.4)	0.527
Male	8 (57.1)	35 (68.6)
T stage primary tumor, No. (%)
T0	0 (0)	1 (2.0)	0.521
T1	0 (0)	3 (5.9)
T2	5 (35.7)	7 (13.7)
T3	8 (57.1)	30 (58.8)
T4	1 (7.1)	7 (13.7)
n.a.	0 (0)	3 (5.9)
N stage primary tumor, No. (%)
node negative	5 (35.7)	19 (37.3)	0.794
node positive	9 (64.3)	29 (56.9)
n.a.	0 (0)	3 (5.9)
M stage primary tumor, No. (%)
M0	14 (100)‡	21 (41.2)	n.a.
M1	n.a.	29 (56.9)
n.a.	0 (0)	1 (2.0)
Median number of metastases (range)	2 (1–10)	2 (1–10)	0.491
Largest median diameter, cm (range)	2.6 (0.8–7.0)	2.0 (0.3–13.0)	0.345
Median % vital tumor cells (range)	n.a.	25 (0–90)	n.a.
Median disease free interval, months	25.1 (7.9–117.2)	18.0 (0–116.5)	0.166
Type of cytotoxic chemotherapy, No. (%) within 6 months of liver resection
fluoropyrimidine+oxaliplatin	n.a.	46 (90.2)	n.a.
fluoropyrimidine+irinotecan	n.a.	5 (9.8)
Regimens containing bevacizumab	n.a.	51 (100)

*Wilcoxon's rank sum test was used for continuous variables, Chi-square test for ordinal variables.

^‡According to the inclusion criteria for panel I, all patients were M0 at the time of diagnosis of primary tumor.